Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Training on PD-L1 scoring in non-small cell lung cancer with high intra- and inter-reader agreement: results of a worldwide microscopic/digital image-based training of 751 pathologists.

British journal of biomedical science·2026
Same author

How Should Primary Pulmonary Sarcoma be Staged? Results of an International Multicentre Analysis.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026
Same author

Outcome of patients with curative-intent treatment for primary pulmonary sarcoma: Results from an international multicenter retrospective study.

JTCVS open·2025
Same author

Results of the First Folate Receptor Alpha Testing Trial by the German Quality Assurance Initiative in Pathology (QuIP<sup>®</sup>).

Cancers·2025
Same author

A subgroup of anaplastic thyroid carcinomas harbors MET alterations with potential therapeutic options.

Pathology, research and practice·2025
Same author

A Global Ring Study: Concordance Between Ventana PATHWAY Anti-HER2/neu (4B5) Companion Diagnostic Assay and Comparators in Detecting HER2-Low Breast Cancer.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2025

Related Experiment Video

Updated: Nov 6, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.0K

[Predictive diagnostics for checkpoint inhibitors].

Hans-Ulrich Schildhaus1, Wilko Weichert2

  • 1Institut für Pathologie, Universitätsklinikum Essen, Essen, Deutschland.

Der Pathologe
|May 6, 2021
PubMed
Summary
This summary is machine-generated.

Checkpoint inhibitors are revolutionizing cancer treatment, but patient response varies. Research focuses on predictive biomarkers like PD-L1, microsatellite instability, and tumor mutational burden to guide immune checkpoint blockade therapy selection.

Keywords:
ImmunooncologyMicrosatellite instabilityPD-L1Patient selectionTumor mutational burden

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.9K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

783

Related Experiment Videos

Last Updated: Nov 6, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.0K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.9K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

783

Area of Science:

  • Oncology
  • Immunology
  • Medical Diagnostics

Background:

  • Immune checkpoint inhibitors represent a significant advancement in cancer therapy.
  • However, variable patient responses necessitate the identification of predictive biomarkers.
  • Current diagnostic approaches for selecting patients for these therapies are diverse and evolving.

Purpose of the Study:

  • To review the current landscape of diagnostic response predictors for immune checkpoint blockade.
  • To discuss recent developments in identifying biomarkers for patient selection.
  • To highlight the challenges and future directions in this field.

Main Methods:

  • Literature review of current research on predictive markers for immune checkpoint inhibitors.
  • Analysis of established and emerging biomarkers such as PD-L1, microsatellite instability, and tumor mutational burden.
  • Discussion of their implementation in routine clinical diagnostics.

Main Results:

  • Programmed Death-Ligand 1 (PD-L1) expression is an established biomarker but used in varied diagnostic contexts.
  • Microsatellite instability (MSI) and tumor mutational burden (TMB) are also utilized, with some implemented in diagnostics.
  • Numerous other molecular parameters have been proposed but are not yet in routine use.

Conclusions:

  • Predictive markers are crucial for optimizing immune checkpoint blockade therapy.
  • While PD-L1, MSI, and TMB are key biomarkers, further research is needed for broader application.
  • The development and validation of novel biomarkers will enhance patient stratification and treatment efficacy.